Know Labs, Inc. focuses on the development and commercialization of proprietary technologies in the United States. Its technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a molecular signature. The company refers to its technology as Bio-RFID. The Bio-RFID technology can be integrated into various wearable, mobile, or bench-top form factors. Its first application of Bio-RFID technology is a product marketed as a glucose monitor that provide the user with real time information on their blood glucose levels. The company was formerly known as Visualant, Incorporated and changed its name to Know Labs, Inc. in May 2018. Know Labs, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Know Labs, Inc.

Know Labs uses non-invasive diagnostic technology to identify and measure a variety of molecules using radio waves.

Know Labs

Know Labs, Inc. | 2,947 followers on LinkedIn. Transforming Non-Invasive Medical Diagnostics | Know Labs is transforming non-invasive medical diagnostics. The proprietary technology platform uses radiofrequency (RF) dielectric spectroscopy and can be integrated into a variety of wearable, mobile, or bench-top form factors. The first application is a non-invasive continuous blood glucose monitoring device that will provide the user with real-time information on their blood glucose levels, assisting billions of people with diabetes and prediabetes to manage this medical condition.

Ron Erickson

Chief Financial Officer & Senior Vice President, Intellectual Property (IP), Know Labs (NYSE: KNW)

Peter Conley

Karmeen Kulkarni

CMO @Know Labs ($KNW) I Mama to Izzy I Ex-Oura, Dropbox, Electronic Arts I Brand Builder I Board Member

Jessica English

New update --> Our team is exploring a great growth opportunity. More to come soon. https://lnkd.in/gpixsQfD

Today, Know Labs announced the publication of our peer-reviewed study in the esteemed Diabetes Technology and Therapeutics Journal. The study demonstrates the accuracy of our proprietary radiofrequency (RF) dielectric sensor in classifying an individual’s glycemic status—serving as proof-of-concept for a novel, non-invasive screening device. We are incredibly proud of the team involved with producing these results and remain committed to developing accurate, affordable, and accessible solutions for the 500M+ people worldwide living with diabetes and the 240M+ people worldwide remaining undiagnosed. See the published article here: https://lnkd.in/gHch98X6

Today Know Labs led an interactive discussion during Friends For Life Orlando 2024 where we imagined a world with a no-needle CGM. Thank you Children With Diabetes for having us and for continuing to support our mission to deliver the first FDA-cleared non-invasive CGM to the marketplace. A very special thank-you to all those who participated in the discussion by sharing your stories, asking thoughtful questions, and helping us ensure we get it right. #FFLOrlando24

This article in CNET featured Know Labs as one company working to develop a truly no-needle device that can accurately measure blood glucose. The article covered our recent clinical results presentation at the American Diabetes Association 's 84th Scientific Sessions, the platform nature of our proprietary radiofrequency (RF) technology, and the impact non-invasive medical diagnostics could have on predictive health. Read the full article here: https://lnkd.in/gTsvcNtJ #medicaldevice #glucosemonitoring #CGM

Today we announced that we’ve been selected for an abstract poster presentation at the American Diabetes Association ’s (ADA) 84th Scientific Sessions in Orlando, Florida on Saturday, June 22, 2024 at 12:30 p.m. - 1:30 p.m. EDT. For those attending, Dr. Virend K. Somers of the Mayo Clinic will be presenting the abstract titled, “A New Machine Learning Model and Expanded Dataset for a Non-Invasive BGM.” These interim study results are the latest from our clinical research protocol involving participants with pre-diabetes and T2D, using venous blood as a comparative reference. The results demonstrate a stable MARD with more than twice as much data collected from 22 participants and a new machine learning model. See the full announcement here: https://lnkd.in/gRZqPWeX #ADASciSessions

We're excited to share that Know Labs, Inc. has joined the Wyss Diagnostic Accelerator (DxA)'s Industrial Participant Program(IPP). They are the twentieth IPP member, joining other companies with a range of diagnostically relevant expertise. The Wyss DxA IPP serves as a collaboration hub between healthcare testing companies, and the scientific and clinical community within the Wyss Institute, as well as our affiliated institutions and the broader Harvard ecosystem. https://bit.ly/3z0TWBw

Wyss Institute at Harvard University

Great event, lots of new connections! Thank you BIO International Convention .

Leo Trautwein

Today we announced that we've joined the renowned Industrial Participant Program of the Wyss Institute at Harvard University 's Diagnostics Accelerator. As a member, Know Labs joins other leaders dedicated to accelerating the development of disruptive, innovative solutions that address urgent and unmet clinical needs. We'll contribute experience in developing novel radiofrequency (RF) dielectric sensor technology for applications in non-invasive blood glucose monitoring for diabetes management, as well as for broader medical diagnostic applications. See more in a release here: https://lnkd.in/gbhtq_5w

It was my pleasure to show Know Labs, Inc. progress at Hospitalar 2024, as part of the State of Washington’s delegation. Thank you all that stopped by and see you again in 2025. … And Sidera for organizing it.

	Sep '14	Sep '15	Sep '16	Sep '17	Sep '18	Sep '19	Sep '20	Sep '21
revenue	7.98M -	6.29M 21.20%	6.02M 4.25%	4.87M 19.08%	4.30M 11.72%	1.80M 58.06%	121.94K 93.24%
cost of revenue	6.69M -	5.27M 21.21%	5.04M 4.52%	3.97M 21.23%	3.48M 12.23%	1.38M 60.41%	69.73K 94.94%
gross profit	1.29M -	1.02M 21.15%	987.90K 2.81%	907.75K 8.11%	821.62K 9.49%	426.55K 48.08%	52.21K 87.76%
selling and marketing expenses
general and administrative expenses
selling general and administrative expenses	3.18M -	2.98M 6.16%	3.36M 12.45%	3.09M 7.96%	2.51M 18.76%	4.18M 66.68%	4.84M 15.85%	6.48M 33.68%
research and development expenses	670.74K -	362.66K 45.93%	325.80K 10.16%	79.41K 75.63%	570.51K 618.49%	1.26M 120.48%	2.03M 61.68%	3.97M 95.21%
other expenses
cost and expenses	10.54M -	8.62M 18.25%	8.72M 1.11%	7.13M 18.16%	6.56M 8.03%	6.82M 3.92%	6.95M 1.91%	10.45M 50.35%
operating expenses	3.85M -	3.35M 13.09%	3.68M 10.00%	3.17M 13.95%	3.08M 2.79%	5.44M 76.65%	6.88M 26.45%	10.45M 51.87%
interest expense	104.81K -	170.16K 62.35%	323.93K 90.37%	376.97K 16.38%	1.20M 217.09%	2.95M 146.40%	6.09M 106.93%	14.91M 144.71%
ebitda	-499.71K -	-2.08M 315.85%	-1.24M 40.15%	-3.44M 176.81%	-1.93M 43.95%	-4.41M 128.42%	-7.22M 63.92%	-10.25M 41.80%
operating income	-2.56M -	-2.33M 9.03%	-2.69M 15.59%	-3.24M 20.43%	-2.26M 30.39%	-5.01M 122.04%	-6.83M 36.16%	-10.45M 53.04%
depreciation and amortization	418.27K -	353.23K 15.55%	178.76K 49.39%	81.28K 54.53%	132.62K 63.15%	259.35K 95.56%	242.99K 6.31%	200.81K 17.36%
total other income expenses net	1.54M -	-271.50K 117.65%	946.67K 448.69%	-657.76K 169.48%	-999.86K 52.01%	-2.60M 159.97%	-6.74M 159.17%	-14.91M 121.38%
income before tax	-1.02M -	-2.60M 154.35%	-1.75M 32.86%	-3.90M 123.37%	-3.26M 16.50%	-7.61M 133.68%	-13.56M 78.17%	-25.36M 86.99%
income tax expense	-5.51K -	29.59K 636.73%	1.27M 4,194.01%	-280.78K 122.10%	195.47K 169.62%	346.01K 77.01%	-642.03K 285.55%
net income	-1.02M -	-2.63M 158.63%	-1.75M 33.62%	-3.90M 123.37%	-3.26M 16.50%	-7.61M 133.68%	-13.56M 78.17%	-25.36M 86.99%
weighted average shs out	1.11M -	1.13M 2.04%	1.43M 26.26%	3.84M 169.10%	8.63M 124.48%	18.05M 109.18%	21.79M 20.70%	29.37M 34.78%
weighted average shs out dil	1.11M -	1.13M 2.04%	1.43M 26.26%	3.84M 169.10%	8.63M 124.48%	18.05M 109.18%	21.79M 20.70%	29.37M 34.78%
eps	-0.92 -	-2.33 153.26%	-1.22 47.64%	-1.01 17.21%	-0.38 62.38%	-0.42 10.53%	-0.62 47.62%	-0.86 38.71%
epsdiluted	-0.92 -	-2.33 153.26%	-1.22 47.64%	-1.01 17.21%	-0.38 62.38%	-0.42 10.53%	-0.62 47.62%	-0.86 38.71%

CO:KNOWLABS

Know Labs

Last Close

2.62

16/09 04:00

Market Cap

34.17M

Beta: -

Volume Today

409.44K

Avg: -

Preview